Home Metabolism Casein Kinase

Casein Kinase

Other Metabolism Related Inhibitors

Dehydrogenase Transferase DPP Aminopeptidase Procollagen C Proteinase P450 (e.g. CYP17) Phospholipase (e.g. PLA) Factor Xa PDE DHFR

Isoform-selective Products

Cat.No. Product Name Information Product Use Citations Product Validations
S1105 LY294002 LY294002 (SF 1101, NSC 697286) is the first synthetic molecule known to inhibit PI3Kα/δ/β with IC50 of 0.5 μM/0.57 μM/0.97 μM, respectively; more stable in solution than Wortmannin, and also blocks autophagosome formation. It not only binds to class I PI3Ks and other PI3K-related kinases, but also to novel targets seemingly unrelated to the PI3K family. This compound also inhibits CK2 with IC50 of 98 nM. It is a non-specific DNA-PKcs inhibitor and activates autophagy and apoptosis.
Gut, 2025, gutjnl-2025-335163
Cell Mol Immunol, 2025, 22(5):541-556
Nat Commun, 2025, 16(1):1661
Verified customer review of LY294002
S7085 IWP-2 IWP-2 is an inhibitor of Wnt processing and secretion with IC50 of 27 nM in a cell-free assay, selective blockage of Porcn-mediated Wnt palmitoylation, does not affect Wnt/β-catenin in general and displays no effect against Wnt-stimulated cellular responses. IWP-2 specifically inhibits CK1δ.
Sci Bull (Beijing), 2025, S2095-9273(25)00472-4
Nat Commun, 2025, 16(1):1999
Nat Commun, 2025, 16(1):4688
Verified customer review of IWP-2
S2248 Silmitasertib (CX-4945) Silmitasertib (CX-4945) is a potent and selective inhibitor of CK2 (casein kinase 2) with IC50 of 1 nM in a cell-free assay, although it is less potent against Flt3, Pim1 and CDK1 (inactive in cell-based assay). This compound induces autophagy and promotes apoptosis. Phase 1/2.
Nat Cell Biol, 2025, 27(8):1272-1287
Nat Commun, 2025, 16(1):997
Metabolism, 2025, 162:156060
Verified customer review of Silmitasertib (CX-4945)
S0707 Silmitasertib (CX-4945) sodium salt Silmitasertib (CX-4945) sodium salt is a potent, orally bioavailable and selective inhibitor of casein kinase 2 (CK2) with IC50 of 1 nM against CK2α and CK2α'.
Diabetologia, 2024, 10.1007/s00125-024-06128-1
J Diabetes Investig, 2024, 15(6):684-692
Proc Natl Acad Sci U S A, 2022, 119(12):e2114336119
S7642 D 4476 D 4476 is a potent, selective, and cell-permeant CK1 (casein kinase 1) inhibitor with IC50 of 200 nM and 300 nM in a cell-free assay for CK1 from Schizosaccharomyces pombe and CK1δ, respectively. Also acts as an ALK5 inhibitor with IC50 of 500 nM.
Neoplasia, 2025, 66:101175
Cell Rep Med, 2023, 4(4):101015
Cell Rep, 2023, 42(9):113035
Verified customer review of D 4476
S5265 TBB TBB (4,5,6,7-tetrabromobenzotriazole) is a selective cell-permeable CK2 inhibitor with IC50 values of 0.9 and 1.6 μM for rat liver and human recombinant CK2 respectively.
Cell Rep, 2024, 43(2):113779
Mol Cell, 2023, 83(15):2792-2809.e9
Cancers (Basel), 2022, 15(1)200
S8237 IC261 IC261 (SU-5607) is a novel inhibitor of CK1. The IC50 of this compound for CK1 is 16 μM and for Cdk5 is 4.5 mM.
Int J Nanomedicine, 2025, 20:9019-9030
Cell Rep, 2023, 42(7):112812
Cell Metab, 2022, S1550-4131(21)00542-8
S9850 (E/Z)-GO289

(E/Z)-GO289 potently and selectively inhibits casein kinase 2 (CK2) at an IC50 of 7 nM in vitro kinase assay.
Autophagy, 2023, 10.1080/15548627.2023.2281128
S6536 TTP 22 TTP22 is a casein kinase 2 (CK2) inhibitor with an IC50 value of 100 nM. It displays selectivity for CK2 over JNK3, ROCK1, and MET with no inhibitory effects towards these kinases at 10 μM.
J Cell Biol, 2022, 221-11e202202100
S6578 Longdaysin Longdaysin is a Casein Kinase inhibitor with IC50 values of 8.8 μM, 5.6 μM, 52 μM and 29 μM for CKIδ, CKIα, ERK2 and CDK7.
Nat Commun, 2021, 12(1):7003